Group 1 - The core viewpoint of the article highlights the significant stock price increase of Xuan Bamboo Biotech-B (2575.HK), which surged by 25.19% to HKD 96.9, reaching a market capitalization of over HKD 50 billion [1] - The stock has risen 735.34% from its IPO price of HKD 11.6 since its listing on October 15 this year, indicating strong investor interest and market performance [1] - The company announced that its innovative drug, Pirlosil, branded as Xuan Yuening®, has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025), which will take effect on January 1, 2026 [1] Group 2 - The inclusion of Xuan Yuening® in the medical insurance list is expected to enhance the drug's affordability and accessibility for patients, thereby promoting its market penetration and sales growth [1] - The company plans to actively support the implementation of the insurance policy, continue hospital access initiatives, expand core markets, and increase market coverage to improve patient access to medication [1]
轩竹生物大涨25% 股价创上市新高 较发行价已累涨超7倍 市值超500亿！
Jin Rong Jie·2025-12-12 06:53